Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada

Sponsor: Bristol-Myers Squibb
Study ID: NCT06361576
Status: Completed

Conditions

Upper Gastrointestinal Cancer

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Nivolumab — DRUG
As per product label

Study Details

The purpose of this observational study is to describe the demographics, and disease characteristics of participants with metastatic upper gastrointestinal cancer, along with the treatment characteristics of these patients when treated with nivolumab.

Key Dates

Start date: Sep 5, 2023
Status verified: Apr 2024
Primary completion: Jan 25, 2024
Completion: Jan 25, 2024

Study Design

Enrollment: 700 participants (actual)

Arms

Arm: Participants enrolled and treated with nivolumab in the metastatic setting